Erasca investors face Aug. 10, 2026 lead plaintiff deadline in ERAS class action

Multiple law firms are now pursuing investors for a proposed securities class action against Erasca, Inc., with shareholders who purchased or otherwise acquired ERAS shares between January 14, 2025 and April 26, 2026 facing an August 10, 2026 deadline to seek appointment as lead plaintiff. The claims center on alleged misstatements about ERAS-0015, Erasca’s investigational oral pan-RAS molecular glue for RAS-mutant solid tumors, and whether the company’s public statements about the program had a reasonable factual basis. The complaint alleges Erasca improperly compared its ERAS-0015 40 milligram dose cohort with Revolution Medicines’ RMC-6236 400 milligram dose cohort and continued to reassure investors about its intellectual property position, including statements on March 12, 2026 describing an in-licensed patent family from Joyo with one issued U.S. patent, one pending U.S. non-provisional patent application, one issued foreign patent and 13 pending foreign patent applications. Plaintiffs contend those comparisons exposed Erasca to patent and trade-secret disputes and made its positive statements about ERAS-0015 false or materially misleading. Two April 27, 2026 disclosures underpin the case. Before the market opened, Erasca disclosed that it had received a letter from legal counsel for Revolution Medicines challenging its intellectual property claims, alleging trade secret misappropriation and objecting to comparative statements about ERAS-0015 and RMC-6236. After the market closed, Erasca disclosed that a patient treated with ERAS-0015 suffered an adverse event, went to the emergency room about a month after receiving treatment, and later died. Erasca shares fell $2.34, or 10.9%, to close at $19.15 on April 27, then dropped another $9.25, or 48.3%, to close at $9.90 on April 28, erasing more than $2.8 billion in market capitalization, according to Hagens Berman. DJS Law Group has now joined Glancy Prongay Wolke & Rotter LLP and Hagens Berman in reminding investors of the case.